Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) in 13 of these genes to predict tumour response and clinical outcome measured as progression free survival...

Full description

Bibliographic Details
Main Authors:	María Gaibar, Miguel Galán, Alicia Romero-Lorca, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander, Apolonia Novillo
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	International Journal of Molecular Sciences
Subjects:	bevacizumab colorectal cancer angiogenesis polymorphisms
Online Access:	https://www.mdpi.com/1422-0067/22/3/1381

Similar Items

<i>HER2</i> and <i>BARD1</i> Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
by: Apolonia Novillo, et al.
Published: (2023-01-01)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022-01-01)

<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
by: Giorgia Marisi, et al.
Published: (2019-07-01)

Association of Single Nucleotide Polymorphisms from Angiogenesis-Related Genes, <i>ANGPT2</i>, <i>TLR2</i> and <i>TLR9,</i> with Spontaneous Preterm Labor
by: Wioletta Izabela Wujcicka, et al.
Published: (2022-06-01)

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
by: Varun Monga, et al.
Published: (2018-02-01)

Resolution of macular edema in <i>Coats′ disease</i> with intravitreal bevacizumab
by: Entezari Morteza, et al.
Published: (2010-01-01)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018-08-01)

Polymorphisms in the Angiogenesis-Related Genes <i>EFNB2</i>, <i>MMP2</i> and <i>JAG1</i> Are Associated with Survival of Colorectal Cancer Patients
by: Dominique Scherer, et al.
Published: (2020-07-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ
by: Feng Chen, et al.
Published: (2016-07-01)

Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
by: Adam L. Cohen, et al.
Published: (2013-08-01)

The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
by: Luiz F.M. Barros, et al.
Published: (2007-09-01)

A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
by: Soysal D., et al.
Published: (2014-12-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
by: Ananaya Datta-Mitra, et al.
Published: (2014-01-01)

Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial
by: José Edísio da Silva Tavares Neto, et al.
Published: (2023-04-01)

<i>RAS</i> Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
by: Chiara Nicolazzo, et al.
Published: (2022-02-01)

In Vivo investigation of radiolabeled Bevacizumab in healthy rat tissues
by: Ilknur Demir, et al.
Published: (2011-02-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
by: N. García-Romero, et al.
Published: (2020-06-01)

Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial
by: Mohammad-Reza Razeghinejad, et al.
Published: (2014-01-01)

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.
by: Issam Makhoul, et al.
Published: (2017-01-01)

A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
by: Gustavo Maluf, et al.
Published: (2019-10-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
by: Neel Patel, et al.
Published: (2017-05-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
by: Eudocia Q. Lee, et al.
Published: (2019-10-01)

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
by: Klaudia Żak, et al.
Published: (2024-03-01)

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2020-11-01)

Efficacy of intravitreal bevacizumab for the treatment of Zone I Type 1 retinopathy of prematurity
by: Reza Karkhaneh, et al.
Published: (2018-01-01)

Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2021-02-01)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
by: Chih-Lin Mao, et al.
Published: (2022-06-01)

MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of <i>HIF-1α</i> and <i>ANGPT2</i>
by: Ying-Hsien Huang, et al.
Published: (2022-01-01)

Bruxism Throughout the Lifespan and Variants in <i>MMP2</i>, <i>MMP9</i> and <i>COMT</i>
by: Alexandre R. Vieira, et al.
Published: (2020-05-01)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
by: Liu J, et al.
Published: (2019-11-01)

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
by: Haiyan Jia, et al.
Published: (2021-10-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
by: Seung Won Choi, et al.
Published: (2018-05-01)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
by: Satoshi Watanabe, et al.
Published: (2022-12-01)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018-05-01)

Inhibitory Effects of Pectic Polysaccharide Isolated from <i>Diospyros kaki</i> Leaves on Tumor Cell Angiogenesis via VEGF and MMP-9 Regulation
by: Jun Yeon Park, et al.
Published: (2020-12-01)

The Effect of Subconjunctival Bevacizumab on Angiogenesis in Rabbit Model
by: Nurwasis Nurwasis, et al.
Published: (2021-01-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

<i>TP53</i> DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
by: Hung-Chih Hsu, et al.
Published: (2019-07-01)